SC issues notice to Centre, PATH on clinical trials

The bench tagged the case with other petitions on clinical trials being heard by a different bench

Image
Press Trust of India New Delhi
Last Updated : Nov 11 2013 | 5:07 PM IST
The Supreme Court today issued notice to PATH, an international NGO working in the health sector, on a PIL alleging that it indulged in unethical conduct of clinical trials in collaboration with ICMR between 2009-10 in Andhra Pradesh and Gujarat.

A bench of Chief Justice P Sathasivam and Justice Ranjan Gogoi also sought response from the Centre and state governments on the petition filed by an NGO Sama which works in the field on feminist activism and health.

The bench tagged the case with other petitions on clinical trials being heard by a different bench.

Also Read

The petitioner alleged that there were serious failures on the part of PATH (Program for Appropriate Technology in Health (PATH)) and Indian Council of Medical Research (ICMR) in complying with legal and ethical requirements to obtain written 'informed' consent and it caused serious adverse events.

"The Ethics Committees failed in their duty to protect the rights of trial participants by allowing the trial to be conducted in young girls from socio-economically backward families and where medical facilities were poor or non- existent," the petition said, adding, "The current ethical and legal framework to protect subjects of clinical trials is grossly inadequate and needs to be re-examined."

Earlier, a bench headed by Justice R M Lodha, which was hearing a batch of PILs against clinical trials, had said that trials in the country must be held to help people here and must not be allowed for the benefits of multinational companies.

The apex court had said that norms formulated by the Centre are "deficient" to protect the rights of the subjects.

It had said no trial of new drugs be allowed till consent of people subjected to trial was recorded in audio/visual medium and permitted the trial of five chemicals but refused to pass order on 157 drugs which were allowed by the Centre.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 11 2013 | 5:01 PM IST

Next Story